**Local Studies:**

The effect of exogenous glucose-dependent insulintropic polypeptide in combination with glucagon-like peptide-1 on glycaemia in critically ill patients
A Deane, M Lee, A Zaknic, M Summers, MJ Chapman, B Reddi, K Sundararajah, M Horowitz, C Rayner, J Meier

Investigating amino acid absorption in health
MJ Chapman, A Deane, A Zaknic, M Summers, R Holloway, G Davidson, RJL Fraser

Effects of exogenous Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers
M Plummer, A Deane, T Crowhurst, M Summers, K Jones, J Meier, MJ Chapman, C Rayner, M Horowitz

Effects of exogenous Glucagon-Like Peptide-1 (GLP-1) administration on glucose metabolism and small intestinal transit in critically ill patients
A Deane, MJ Chapman, RJL Fraser, C Burgstad, LK Besanko, M Horowitz

M Shunmugam, S O’Connor, R Yandell, YH Yau, BJC Freeman, K Lange, R Marshall, M Chapman

**ANZICS Clinical Trials Group Studies:**

2009 –

ARISE
Australasian Resuscitation In Sepsis Evaluation
PI: S Baker

EPO-TBI
A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury – ErythroPOietin in Traumatic Brain Injury (EPO-TBI)
PI: R Strickland

**Pharmaceutical Company Studies:**

2011 –

A Multi-centre, Randomised, Double-Blind, Placebo-controlled Phase 2b Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of Cytofab™ (AZD9773) in Adult Patients with Sever Sepsis and/or Septic Shock
PI: A Deane